Cumberland Pharmaceuticals Founder, Chairman and CEO A. J. Kazimi (at left) told executives assembled for Owen GSM Professor Germain Boer's entrepreneurs breakfast this morning that one reason refused to withdraw his IPO from the SEC shelf was that his research showed that companies that did that never came back for a public offering. Instead, often because of cash woes, they sold, took private equity, or somesuch. Kazimi said Cumberland was doing fine on cash, and could afford to wait the reopening on the IPO window, and would need investment from the IPO to fuel its longer-term product-acquisitions strategy. The company made a record 20 amendments to its shelf filing, while waiting. Although the company attracted $85MM in gross proceeds and netted more than $75MM from its IPO Aug. 10, 2009, Kazimi said today that his priority is scaling-up his operations around Cumberland three current products, rather than immediately rushing to "drop in a fourth product." Once the IPO was imminent, Kazimi explained, he personally made about 100 presentations to investors in five days, including pitches he was obliged to make by phone during plane flights. Speakers during Boer's breakfasts are speaking off the record, unless they give permission to be quoted. Kazimi agreed VNC could write about his remarks. Kazimi's CPIX (NASDAQ) was trading at about $14 this morning.
Showing posts with label Joe Rolwing. Show all posts
Showing posts with label Joe Rolwing. Show all posts
Friday, January 15, 2010
Kazimi on Cumberland Pharma
Cumberland Pharmaceuticals Founder, Chairman and CEO A. J. Kazimi (at left) told executives assembled for Owen GSM Professor Germain Boer's entrepreneurs breakfast this morning that one reason refused to withdraw his IPO from the SEC shelf was that his research showed that companies that did that never came back for a public offering. Instead, often because of cash woes, they sold, took private equity, or somesuch. Kazimi said Cumberland was doing fine on cash, and could afford to wait the reopening on the IPO window, and would need investment from the IPO to fuel its longer-term product-acquisitions strategy. The company made a record 20 amendments to its shelf filing, while waiting. Although the company attracted $85MM in gross proceeds and netted more than $75MM from its IPO Aug. 10, 2009, Kazimi said today that his priority is scaling-up his operations around Cumberland three current products, rather than immediately rushing to "drop in a fourth product." Once the IPO was imminent, Kazimi explained, he personally made about 100 presentations to investors in five days, including pitches he was obliged to make by phone during plane flights. Speakers during Boer's breakfasts are speaking off the record, unless they give permission to be quoted. Kazimi agreed VNC could write about his remarks. Kazimi's CPIX (NASDAQ) was trading at about $14 this morning.
Thursday, September 17, 2009
TBA leadership condundrum
The Tennessee Biotechnology Association Board of Directors is regrouping and will confer tomorrow on how to proceed with recruiting a new chair, setting strategy and priorities and more. Here's our story. That's TBA President Joe Rolwing, at left.
Tuesday, September 16, 2008
TN BIO's Rolwing
Our story yesterday on 'Bionic Woman' Leslie Wisner-Lynch's role in advancing biotechnology in Middle Tennessee -- with observers' comments on the industry's halting progress -- drew a crowd. Not mentioned in that article is the fact that Tennessee Biotechnology Association is getting by with basically 75 percent of an executive director: TBA Chairman and President Bob Acuff told VNC he hopes the organization will soon be able to afford 100 percent of Executive Director Joe Rolwing's time. That's Joe at left in the adjoining photo, talking with a student during a recent TNBIO Student Chapter event (there's another scheduled Sept. 22). TBA contracts for the indefatigable Rolwing's services from Cumberland Emerging Technologies, the incubator that's controlled by Cumberland Pharmaceuticals, Vanderbilt University and Tennessee Technology Development Corporation. Rolwing was only half-time a year or so ago. The balance of his time is apparently still spent as director of the CET Life Sciences Center.
Subscribe to:
Posts (Atom)